Science

David Planchard: Unparalleled benefit of Osimertinib for EGFR-mutated advanced NSCLC

David Planchard/Oncostream.com

Mar 14, 2025, 13:20

David Planchard: Unparalleled benefit of Osimertinib for EGFR-mutated advanced NSCLC

David Planchard, Thoracic Oncologist and Professor at the University Paris Saclay, shared an article by Pasi A Jänne, et al. on X:

“Unparalleled benefit to date of osimertinib (FLAURA) and especially in combination with chemotherapy (FLAURA2) for our EGFR-mutated advanced NSCLC patients in first-line treatment with brain/meningeal metastases.”

A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.

Authors: Pasi A Jänne, et al.

cancer David Planchard EGFR fight against cancer FLAURA2 Global fight against cancer non small cell lung cancer NSCLC OncoDaily Oncology osimertinib Pasi A. Jänne University Paris Saclay

New Paper Alert: Management of Immune Checkpoint Inhibitor-Associated Toxicities in Older Adults with Cancer

Kimryn Rathmell was Awarded 2025 ACS Medal of Honor

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Special Coverage